LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, announced today that the Therapeutic Goods Administration (TGA) in Australia has accepted for review the company’s marketing application for ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of metastatic breast cancer. The review period in Australia typically is 12 to 18 months from the date that the application is accepted. This is the second global regulatory filing for ABRAXANE to be accepted for review in the past four months. A marketing authorization application is also currently under review with the European Medicines Agency (EMEA) for use of ABRAXANE in the treatment of breast cancer.
